Skip to content

Cancer Stem Cell Sphere Assay

Epistem's cancer stem cell sphere assay can be used to assess the effect of a novel therapeutic agent on the sphere-forming ability of neoplastic cells isolated from human tumour cell lines.

What's Available

Epistem offers a range of service options for the assessment of preclinical novel therapeutic agents.

Evidence suggests that tumours are derived from, and maintained by, a self-renewing subpopulation of undifferentiated progenitor cells which are resistant to conventional forms of chemotherapy.

Epistem’s cancer progenitor cell assay can be used alongside xenograft models to assess the effect of novel therapeutic agents in vivo.

Cancer Stem Cell Sphere Assays assess the effectiveness of novel therapeutic agents interfering with the sphere-forming ability of neoplastic cells isolated from human tumour cell lines. This valuable tool can determine the level of resistance self-renewing subpopulations of undifferentiated progenitor cells possess to conventional therapeutics.

Epistem’s cancer progenitor cell assay can be used alongside xenograft models to assess the effect of novel therapeutic agents in vivo.

The advantages of these assays include:

• In vitro model: Sphere stem cell assays provide a useful in vitro model for studying cancer stem cells in a controlled environment.

• High throughput: Sphere stem cell assays are highly scalable, making it possible to study large numbers of cells in a short amount of time.

• Clonal analysis: Sphere stem cell assays can be used to study the behaviour of individual stem cells, including their ability to self-renew and differentiate.

Download the latest brochure

From brochures to posters, find all the information you need in a downloadable & printable format.

Contact information

For more information regarding our services, please do not hesitate to contact us.

Contact us